Loading
A phase 3 trial of Pembrolizumab, Olaparib in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) is a phase 3 interventional study registered as NCT04624204 by Merck Sharp & Dohme LLC, with 672 participants planned, started 2020-12-08 and due to reach its primary completion in 2027-10-28. Interventions recorded: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Pembrolizumab placebo (saline), Olaparib 300 mg BID. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Olaparib, Pembrolizumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Pembrolizumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Pembrolizumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Merck & Co. (MSD), Pembrolizumab.
Shares PARP inhibitors, Olaparib, Merck & Co. (MSD).
Shares PARP inhibitors, Olaparib, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Pembrolizumab, Immune checkpoint inhibitors.